SCHEMBL22320202

SCHEMBL22320202

C[CH]C(C)n1cc(C#N)c2ccccc21

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
IMPDH2 P12268 1/20 0.54
ALDH1A1 P00352 5/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
KMT2A Q03164 4/20 0.44
TSHR P16473 3/20 0.44
TDP1 Q9NUW8 3/20 0.44
MEN1 O00255 3/20 0.44
MAPT P10636 6/20 0.43
STAT3 P40763 1/20 0.42
POLB P06746 1/20 0.42
HTT P42858 4/20 0.41
LMNA P02545 2/20 0.41
MAPK1 P28482 1/20 0.41
L3MBTL1 Q9Y468 4/20 0.39
KDM4E B2RXH2 1/20 0.38
HSD17B10 Q99714 1/20 0.38
SLC6A2 P23975 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8266974 0.83 IMPDH2 (0.61) IMPDH2ALDH1A1SMN1; SMN2KMT2ATSHR
SCHEMBL31106988 0.83 IMPDH2 (0.61) IMPDH2ALDH1A1SMN1; SMN2KMT2ATSHR
SCHEMBL16473786 0.75 IMPDH2 (0.50) IMPDH2ALDH1A1SMN1; SMN2KMT2ATSHR
SCHEMBL30041728 0.73 IMPDH2 (0.51) IMPDH2ALDH1A1SMN1; SMN2KMT2ATSHR
SCHEMBL1254742 0.73 IMPDH2 (0.51) IMPDH2ALDH1A1SMN1; SMN2KMT2ATSHR
SCHEMBL1778037 0.71 IMPDH2 (1.00) IMPDH2ALDH1A1SMN1; SMN2KMT2ATSHR
SCHEMBL30344324 0.71 IMPDH2 (1.00) IMPDH2ALDH1A1SMN1; SMN2KMT2ATSHR
SCHEMBL579481 0.70 IMPDH2 (0.56) IMPDH2ALDH1A1SMN1; SMN2KMT2ATSHR
SCHEMBL3980032 0.67 IMPDH2 (0.61) IMPDH2ALDH1A1SMN1; SMN2KMT2ATSHR
SCHEMBL6922436 0.67 IMPDH2 (0.61) IMPDH2ALDH1A1SMN1; SMN2KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11629138-B2 Microbiocidal picolinamide derivatives SYNGENTA PARTICIPATIONS AG (CH) 2023-04-18 US disclosed
EP-3692029-B1 MICROBIOCIDAL PICOLINAMIDE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2023-04-12 EP disclosed
US-20200255400-A1 Microbiocidal Picolinamide Derivatives SYNGENTA PARTICIPATIONS AG (CH) 2020-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200255400-A1 Microbiocidal Picolinamide Derivatives PRF1, CASP1, FPR1 IMPDH2 882/4885ALDH1A1 1067/4885SMN1; SMN2 3397/4885
US-11629138-B2 Microbiocidal picolinamide derivatives PRF1, CASP1, FPR1 IMPDH2 882/4885ALDH1A1 1067/4885SMN1; SMN2 3397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.